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ABSTRACT 
 
Daniel Rojas: Prenatal arsenic exposure and the epigenome: Identifying sites of 5-methyl cytosine 
alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth 
outcomes 
(Under the direction of Rebecca C. Fry) 
 
Prenatal exposure to inorganic arsenic (iAs) is detrimental to the health of newborns and 
increases the risk of disease later in life. Here we examined newborn cord blood leukocyte samples from 
the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort in Mexico. Changes in iAs-associated 
DNA methylation were compared to corresponding gene expression levels and birth outcomes. 2,705 
genes were identified with iAs-associated differences in DNA methylation. In contrast to minimal 
association genome-wide, site-specific analyses identified DNA methylation changes that were most 
predictive of gene expression levels. 16 genes were identified with correlated iAs-associated changes in 
DNA methylation and mRNA expression, and with enrichment for binding sites of several transcription 
factors. Furthermore, DNA methylation levels were associated with birth outcomes. These data highlight 
the complex interplay between DNA methylation and functional changes in gene expression and health 
outcomes and underscore the need for functional analyses coupled to epigenetic assessments.  
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CHAPTER 1: INTRODUCTION 
  
Exposure to inorganic arsenic (iAs) at levels that exceed the World Health Organization’s (WHO) 
recommended limit of 10 µg/L currently impacts the health of individuals in countries around the globe	
(ATSDR 2007; WHO 2006).	 Chronic iAs exposure is of considerable concern as it is associated with the 
development of cancers, including the liver, lung, prostate, skin, and urinary bladder as well as other 
chronic diseases in adults (ATSDR 2007). In addition to the health consequences from chronic exposure, 
in utero exposure to iAs is associated with detrimental health consequences in infancy including increased 
risk for infection and increased risk for both cancer and non-cancer endpoints later in life (reviewed in 
(Bailey and Fry 2014)). 
The development of iAs-associated diseases likely result from several mechanisms of toxicity 
including the alteration protein function via direct binding to sulfhydryl groups as well as the generation 
of oxidative stress. Oxidative stress, in turn, can damage cellular macromolecules such as proteins, lipids 
and DNA (Jomova et al. 2011). IAs exposure has also been shown to alter the expression of genes 
involved in key biological pathways such as DNA repair (Andrew et al. 2003). Prenatal iAs exposure has 
been associated with altered gene expression in human cord blood leukocytes and various target tissues in 
rodents (Fry et al. 2007; Liu et al. 2004; Liu et al. 2006; Rager et al. 2014).	 It is probable that these 
changes in gene expression are regulated, at least in part, by epigenetic alterations as supported by 
evidence of changes in genomic 5-methylcytosine patterns associated with prenatal arsenic exposure in 
human cord blood leukocytes (Kile et al. 2012).  
During the DNA methylation process in mammals, a methyl group is enzymatically added to the 
5’ position of cytosines mainly in the context of CpG dinucleotides (Smith et al. 2012). Alterations in 
DNA methylation across the genome can lead to changes in genomic integrity and the silencing or 
	
	
2
expression of genes or entire chromosomes (Smith et al. 2012). DNA methylation patterns are highly 
dynamic during embryonic development, and changes during this stage may lead to permanent 
reprogramming, resulting in life-long effects (Tobi et al. 2009).	 While it is generally accepted that CpG-
based methylation can lead to decreased gene expression, evidence shows these relationships are far more 
complex. For example, DNA methylation does not invariably lead to gene silencing, and in multiple cases 
it has been observed to result in increased expression or have no relationship with gene expression (Bock 
et al. 2012; Boellmann et al. 2010; Dosunmu et al. 2012). Previously published research has demonstrated 
that both chronic as well as prenatal exposure to iAs is associated with DNA methylation changes in 
humans (Kile et al. 2012; Kile et al. 2014; Pilsner et al. 2009; Smeester et al. 2011). However, to our 
knowledge, the relationship between altered levels of DNA methylation, gene expression, and health 
outcomes has not been previously examined in newborns exposed to arsenic in utero.   
To assess the relationships between prenatal iAs exposure, DNA methylation, gene expression, 
and birth outcomes we utilized samples and data obtained through the Biomarkers of Exposure to 
ARsenic (BEAR) prospective pregnancy cohort. This cohort includes women from Gómez Palacio, in the 
state of Durango, Mexico (Rager et al. 2014). In this area, iAs in drinking water often exceeds 50 µg/L, 
and adverse health effects associated with iAs exposure, including skin lesions and diabetes mellitus, have 
been previously identified (Rager et al. 2014).	 We recently assessed the impact of prenatal exposure to 
arsenic on genome-wide mRNA expression profiles in blood leukocytes of a nested set of newborns 
within the cohort (Rager et al. 2014). In the present study, we expand upon this research to examine the 
relationship between DNA methylation levels and transcriptional changes in a gene-specific manner. At 
baseline (i.e. independent of iAs), the predicted negative correlation between DNA methylation and gene 
expression was observed. In the context of iAs-associated changes in DNA methylation, we demonstrate 
that DNA methylation at individual CpG sites and/or methylation averaged across CpG sites for a given 
gene was not necessarily predictive of gene expression change. Genome-position-specific analysis 
identified the sites that were most predictive of functional change. A subset of genes with altered DNA 
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methylation levels were identified that were both associated with gene expression as well as birth 
outcomes. 
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CHAPTER 2: METHODS 
 
Study subjects  
This study was approved by the University of North Carolina at Chapel Hill’s Institutional 
Review Board (#10-1583) and at the Universidad Juárez del Estado de Durango (UJED), del Estado de 
Durango Gómez Palacio, Durango, Mexico. BEAR participants were recruited near the time of delivery at 
the General Hospital of Gómez Palacio. Detailed information on participation requirements, and maternal 
characteristics for the larger study population are described elsewhere (Rager et al. 2014). 
Subcohort selection and determination of DW-iAs and U-tAs 
The present study focuses on a comparative analysis of mRNA expression and DNA methylation 
profiles from 38 cord blood samples obtained from mother-newborn pairs from the larger BEAR cohort 
of 200 mother-newborn pairs. The samples were selected to include newborns exposed to varying levels 
of arsenic as determined by iAs levels in drinking water (DW-iAs; g/L) and the levels of total maternal 
urinary arsenic (U-tAs; g/L). U-tAs is defined as the sum of the levels of iAs and its monomethylated 
(MMAs) and dimethylated metabolites (DMAs) (Rager et al. 2014). 
Cord blood genomic and epigenomic assessment   
To assess DNA methylation levels, isolated DNA was first bisulfite-converted using the EZ DNA 
methylation kit (Zymo Research, Irvine, CA). The converted DNA was then hybridized onto the Infinium 
HumanMethylation450 BeadChip (Illumina, San Diego, CA). This platform assesses the methylation 
levels of a total of 486,428 individual probes each measuring the methylation levels at a single CpG site. 
Methylation levels were calculated and expressed as β values (β = intensity of the methylated allele (M) / 
(intensity of the unmethylated allele (U) + intensity of the methylated allele (M) + 100) as in (Joubert et 
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al. 2012). Methylation data were normalized using a quantile-based methodology (Bolstad et al. 2003) as 
well as beta-mixture quantile normalization (BMIQ) (Teschendorff et al. 2013). For data filtration, probes 
with high detection p-values (p>0.05) were marked as unreliable and removed from analysis (n=1,761), as 
per manufacturer recommendation. Probes that represent known single nucleotide polymorphisms (SNPs) 
were removed (Pidsley et al. 2013) (n=59,732), leaving a total of 424,935 probes for further analyses. 
Median gene methylation was defined as the median methylation β value across subjects summarized for 
all probes corresponding to a particular gene.  
Sites of U-tAs-associated differential DNA methylation were identified using a multi-variable 
regression model where the dependent variable was DNA methylation and the independent variable was 
U-tAs. The covariates were selected based on their association with both exposure and outcome using a 
bivariate analysis (p<0.05) or based on their a priori status as known confounders and included the 
following variables: newborn gender (binary variable) and birth weight/gestational age (continuous 
variable).  Batch effect was not a significant source of variation as evaluated using principal component 
analysis (PCA). Significant probes were identified based on a false discovery corrected q-value <0.05.  
Comparison of differentially methylated genes to published studies  
Kile et al. identified 500 probes in the Infinium HumanMethylation450 BeadChip for which 
methylation changes can be used as surrogate measurements of changes in the underlying cell population 
mixture (Kile et al. 2014). The probes identified in the present study were compared against the cell 
population-related list identified by Kile et al. (2014) in order to test whether the iAs-associated changes 
were related to potential shifts in cell population. Additionally, the probes/genes identified in the present 
study were also compared to probes/genes previously identified in other human studies as having DNA 
methylation changes associated with iAs exposure (Chanda et al. 2006; Gribble et al. 2014; Marsit et al. 
2006; Pilsner et al. 2009; Smeester et al. 2011). 
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Assessment of DNA methylation across six different genomic regions 
Region-specific DNA methylation analysis was carried out using probes annotated to one of six 
gene-specific regions: (i) 3’ untranslated region (3’UTR), (ii) gene body (Body), (iii) first exon (1st Exon), 
(iv) 5’ untranslated region (5’UTR), (v) 200 base pairs upstream of the transcriptional start site (TSS200) 
and (vi) 200 to 1500 base pairs upstream of the transcriptional start site (TSS1500). A Chi-squared test 
was used to compare the distribution of differentially methylated probes to the overall region distribution 
of probes in the platform. A one-sample proportion test was run to identify each deviation from the 
expected proportion in each region.  
Comparison of DNA methylation data to the gene expression data 
The mRNA expression data were obtained from our prior study in which RNA isolated from 
newborn cord blood samples were quality assessed and hybridized to the Affymetrix GeneChip® Human 
Gene 2.0 ST Array (Rager et al. 2014).  The detailed analytical methods used to identify U-tAs-associated 
gene expression is previously described (Rager et al. 2014). Complete gene expression data from cord 
blood leukoctyes were obtained from the same 38 subjects as used in the present DNA methylation 
analysis (Rager et al. 2014).  
As a first assessment in the analysis, probe methylation levels were compared to gene expression 
at baseline (i.e. arsenic-independent analysis) focusing on genes with highest expression levels (n=5,000) 
and genes with the lowest expression levels (n=5,000). Biological functions enriched amongst the highest 
and lowest expressed genes were identified using Ingenuity Pathway Analysis (Ingenuity Systems®, 
Redwood City, CA). For direct comparisons between DNA methylation and mRNA expression, fold 
changes in mRNA level were compared to β differences. Specifically, subjects within the highest 
exposure quartile (HEQ) were compared relative to subjects within the lowest exposure quartile (LEQ) as 
used previously to calculate iAs-associated gene expression fold changes (Rager et al. 2014). Differences 
in DNA methylation were calculated for each probe set where β difference was calculated as: (average β 
value HEQ)-(average β value LEQ). Matches between the DNA methylation and gene expression 
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platform were based on Human Genome Organization (HUGO) annotations.  Genes overlapping between 
the differentially expressed gene (DEG) list and the differentially methylated gene (DMG) list were also 
tested for linear correlations between expression levels and DNA methylation levels.  
Genes with CpG methylation levels significantly associated with U-tAs and gene expression were 
further analyzed for correlations with seven recorded birth outcomes from the BEAR subjects including 
gestational age, birth weight, birth weight/gestational age, newborn length, five minute APGAR 
(appearance, pulse, grimace, activity, respiration) score, placental weight, and head circumference. 
Enrichment analysis of transcription factor binding sites within the promoter regions of 
differentially methylated genes 
In order to identify potential transcriptional regulators that may be related to arsenic-associated 
changes in DNA methylation, enrichment analysis of upstream sequences for regulatory transcription 
factors was performed amongst the differentially methylated genes that showed correlation with gene 
expression levels. Genomatix software suite (Genomatix Software GmbH, Munich, Germany) was used 
to retrieve the promoter regions defined as 1000 base pairs (bp) upstream of the transcription start site 
(TSS) to 50 bp downstream from the TSS. Transcription factors with significant statistical enrichment 
were defined as those with p-value<0.05 (Ho Sui et al. 2005). 
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CHAPTER 3: RESULTS 
 
Characteristics of the BEAR cohort 
The BEAR pregnancy cohort comprises 200 women and their newborns located in Gómez 
Palacio, Mexico. Using a subset of 38 newborn cord blood samples from this larger cohort, the present 
study utilized cord blood leukocytes as the cell type of interest and integrated DNA methylation levels 
with mRNA expression levels as a functional read-out. The samples analyzed were selected to include 
subjects exposed to varying levels of arsenic as determined by both DW-iAs and U-tAs.  
In the present study, cord blood samples were analyzed from newborns (n=38) whose mothers 
were exposed to DW-iAs at levels ranging between the limit of detection (LOD) of 0.456 and 236 µg/L. 
The mean concentration of U-tAs in the cohort analyzed for gene expression and DNA methylation 
analysis was 73.87 µg/L (median=32.57 µg/L) and mean concentration of DW-iAs was 54.1 µg/L 
(median=24.2 µg/L) (Table 1).  
 
Table 1.  U-tAs stratified by DW-iAs in the BEAR cohort and subcohort. Limit of detection (LOD) for 
iAs=0.456 μg/L. Urinary arsenic was normalized using the Specific Gravity (SG) to adjust for changes in 
urine volume. 
Arsenic Measure  Urinary arsenic levels in  
Larger BEAR cohort  (N=200) 
Urinary arsenic levels in 
Subcohort (N=38) 
 N=count, Mean, median 
(range in µg/L) 
N=count, Mean, median 
(range in µg/L) 
DW-iAs: All N=200  
24.6, 13.0, (<0.456-236.0) 
N=38 
54.1, 24.2, (<0.456-236.0) 
DW-iAs: < 10µg/L N=93  
1.7, <0.456, (<0.456-9.7) 
N=17  
1.4, <0.456,  (<0.456-7.0) 
DW-iAs: > 10µg/L N=107  
44.5, 25.4, (10.3-236.0) 
N=21  
96.8, 65.6, (16.4-236.0)  
U-tAs (SG-
normalized) 
 
N=200  
37.5, 23.3  
(4.3-319.7) 
N=38  
73,87, 32.57  
(6.2-319.7) 
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Of the drinking water samples collected from the parent cohort, approximately half (n=21, 
55.2%) had DW-iAs levels that exceeded the WHO standard (10 µg/L) (Table 1). The levels of DW-iAs 
and U-tAs were significantly correlated in both the current subcohort (r = 0.74, p-value < 0.001, n=38) 
and the larger BEAR cohort (r = 0.51, p-value < 0.001, n=200). Additional demographic characteristics of 
the larger cohort participants are previously described (Rager et al. 2014). 
Identification of genes with U-tAs-associated 5-methyl cytosine levels in fetal cord leukocytes 
 U-tAs-associated changes in 5-methyl cytosine levels were assessed for more than 450, 000 
probes and, after filtering for probe quality and quantile normalization, median beta values were 
calculated across the 38 subjects. The distribution of the median beta values for the analyzed probes 
(n=424,935) exhibited a bimodal pattern where probes displayed either very low or very high median 
methylation levels (Figure 1).  
An adjusted multi-variable regression model was used to identify individual CpG sites with 
arsenic-associated differences in cord blood leukocyte DNA methylation where the exposure was defined 
as maternal U-tAs. 
  
Figure 1. Median probe methylation value density for all probes analyzed (n=424,935). 
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A total of 4,771 probes, corresponding to 2,919 differentially methylated genes (DMGs), 
displayed differential U-tAs associated methylation (q<0.05) (Table S1). Of those probes, 34% (n=1,621) 
displayed hypo-methylation as U-tAs levels increased and 66% (n=3,150) displayed hyper-methylation as 
U-tAs levels increased. 
 
Comparison of differentially methylated probes with previously published studies 
The U-tAs-associated DMGs were compared to a list of 500 probes that are most informative of 
changes in leukocyte population as defined by Kile et al. (Kile et al. 2014) and no overlap was found. 
Koestler et al. (2013) published a list of top 100 probes with arsenic-associated DNA methylation 
changes in cord blood leukocytes from prenatally-exposed newborns. A comparison to the previously 
mentioned dataset revealed overlap in a probe within the gene histone cluster 1, H2ac (HIST1H2AC). 
Similarly, 19 probes representing 18 genes were identified as DMGs in the present study as well as in 
another study that evaluated DNA methylation in circulating blood leukocytes from an adult population in 
Mexico exposed to iAs (Smeester et al. 2011) (Table S2). In addition, genes analyzed in previous studies 
including Ras association domain family member 1 (RASSF1), estrogen receptor 1 (ESR1), cyclin-
dependent kinase inhibitor 2A (CDKN2A), and tumor protein p53 (p53) demonstrated at least one probe 
with arsenic-related methylation changes in the present dataset (p<0.05) (Table S2) (Chanda et al. 2006; 
Gribble et al. 2014; Marsit et al. 2006; Pilsner et al. 2009). Thus, numerous genes identified in the present 
study as DMGs were also identified in prior studies of arsenic-associated DMGs. 
Identification of genomic regions enriched within the U-tAs associated probes 
To note, the probe distribution within the Illumina Infinium HumanMethylation450 BeadChip 
platform does not uniformly assess for DNA methylation patterning across the genome. Specifically, of 
the gene-annotated probes, the BeadChip contains more probes (n=161,677 or 44%) that assess CpG 
methylation in the gene body versus probes that assess methylation in the 3’UTR (n=17,494, 5%) (Figure 
2). To determine if there was an enrichment of probes identified with U-tAs-associated differential 
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methylation for a given genomic region, analysis was performed relative to the probe distribution for the 
Illumina platform. The distribution of differentially methylated probes was significantly different from 
the platform distribution for five of six regions. Specifically, the 3’UTR and gene body were enriched 
within the probes that showed differential U-tAs associated DNA methylation, while the 1st exon, 
TSS200 and the 5’ UTR were under-represented (Chi-Squared= 130.2, df = 5, p-value < 2.2x10-16) 
(Figure 2). 
	
Figure 2. Enrichment of U-tAs associated differentially methylated (DM) probes across the gene 
associated regions. Proportion for all region-annotated probes in gray (n=321,417), annotated 
differentially methylated probes in black (n=319). Regions with significant deviation (p<0.05) from the 
platform distribution are indicated (*).  
Comparison of U-tAs-associated DNA methylation differences and mRNA expression changes 
When comparing arsenic-independent levels of DNA methylation between genes with high 
expression (n=5, 000) versus genes with low expression (n=5, 000), the average methylation levels of the 
highest expressed genes (mean=0.37, SD=0.20) were significantly lower than the average methylation of 
the weakly expressed and/or non-expressed genes (p<0.0001; mean=0.56, SD=0.24) (Figure 3).  
Functional enrichment analysis comparing genes with the highest gene expression and lowest DNA 
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methylation where β<0.3 (n=2,208 genes) versus those with the lowest expression and highest DNA 
methylation where β>0.7 (n=1,926 genes) was performed. High expression/low methylation genes were 
enriched for genes controlling core house-keeping functions such as mRNA synthesis and oxidative 
phosphorylation. Low expression/high methylation genes were enriched in functions not typically 
recognized as being performed in leukocytes such as cytochrome p450 synthesis and triacylglycerol 
degradation (Figure 3). 
	
Figure 3. Density of average gene methylation values according to expression levels. The distribution in 
methylation levels for the genes with highest expression (n=5000) was compared to the genes with lowest 
expression (n=5000). Pathway analysis reveals enrichment of specific cellular functions in either high or 
low levels expression groups.  
 
A total of 334 U-tAs-associated mRNAs were previously identified in cord blood leukocytes of 
BEAR newborns (Rager et al. 2014). It was shown that the majority of the transcripts (n=224) decreased 
in mRNA abundance as U-tAs increased, while 110 transcripts increased in mRNA abundance as U-tAs 
increased (Rager et al. 2014). In order to determine the relationship between U-tAs associated changes in 
gene expression (e.g. mRNA expression), and changes in DNA methylation, DNA methylation levels 
from these same study subjects were quantified and compared for all genes represented on both platforms 
(n=18, 761 genes). Of the 334 genes that showed differential gene expression, 269 were represented in the 
platform used to assess DNA methylation and could be matched to their corresponding methylation β-
value (Table S3). A total of 20% (n=54 genes) of the differentially expressed genes showed at least one 
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site of differential methylation. When analyzing the set of DMGs (n=2,705 genes) only 2% (n=54 genes) 
were also present in the list of differentially expressed genes (DEGs) (Table S3).  
Regions of DNA methylation identified as predictors of gene expression 
For those genes that were represented on both gene expression and DNA methylation platforms 
correlations were calculated between the U-tAs-associated mRNA fold change and U-tAs-associated 
differential methylation ( difference). 
 	
Figure 4. Comparison between U-tAs-associated DNA methylation and gene expression. Comparisons 
were made for:  (A) all comparable genes (n=18761), (B) DMGs (n=2705), (C) DEGs (n=267), and (D) 
overlap of DMG and DEGs (n=54). 
The range of U-tAs-associated  difference was -0.19 to 0.13, representing up to a 19% difference in 
methylation levels between the HEQ and LEQ groups. Correlations between the expression fold change 
and methylation  difference were assessed for: (1) all genes (n=18,761) (Figure 4, A), (2) the DMGs 
(n=2,705) (Figure 4, B), (3) DEGs (n=267) (Figure 4, C) or (4) both DMGs and DEGs (n=54) (Figure 4, 
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D). None of these correlations reached statistical significance (p>0.05), however a marginal correlation 
was observed between those genes that were common between the DMGs and DEGs (n=54) (r2=0.06, 
p=0.08) (Figure 4, D). Similar correlation results were observed when data were normalized using the 
alternate BMIQ method (data not shown). Further analysis focused on the DEGs by focusing the analysis  
by the following gene-associated regions: 3’ untranslated region (3’UTR), gene body (Body), first exon 
(1stExon), 5’ untranslated region (5’UTR), 200 base pairs upstream of the transcriptional start site 
(TSS200), and from 200 to 1500 base pairs upstream of the transcriptional start site (TSS1500) (Table 2).  
Table 2. Summary of correlations between iAs-associated changes in DNA methylation (median beta 
difference) and gene expression changes (FC-fold change) including all differentially expressed genes 
(DEGs). Correlations were calculated including all gene-associated regions (all), or one of the following: 
first exon (1st Exon), 3’ untranslated region (3’ UTR), 5’ untranslated region (5’ UTR), gene body 
(Body), promoter region 1500bp-200bp upstream of the transcription start site (TSS1500), promoter 
region 200bp-0bp upstream of the transcription start site (TSS200). For each of these focus regions, 
correlations were calculated including either all CpG probes or only those in CpG islands. 
 
Of the genomic regions analyzed, differences in DNA methylation that occurred within the first exon 
were significantly correlated with changes in gene expression (p=0.04). Furthermore, when the analysis 
focused only on probes located within CpG islands, a highly significant association (p<0.05) was 
observed between U-tAs associated changes in gene expression and methylation in all regions (p=0.02). 
Significance was also observed for the correlation between probes located within CpG islands in the first 
exon (p=0.02). Furthermore, a significant negative correlation identified for those probes within CpG 
islands in the 5’ UTR  and TSS200 (p=0.03) (Table 2). Association analysis was run between mRNA 
expression and DNA methylation across all subjects for each of the 54 DEG and DEM probes. A total of 
16 genes displayed a significant correlation (Table 3).  
All Probes Only CpG Island Probes 
Region Slope RSq p-value n Slope RSq p-value n 
All 1.20E+00 1.82E-03 4.87E-01 269 -3.77E+00 2.10E-02 2.85E-02 228 
1st Exon 3.50E+00 3.15E-02 4.02E-02 134 5.68E+00 5.03E-02 2.15E-02 105 
3'UTR 1.54E-01 1.43E-04 8.79E-01 165 7.06E+00 1.61E-01 5.74E-02 23 
5'UTR -7.93E-01 1.94E-03 6.33E-01 120 -4.62E+00 7.27E-02 1.43E-02 82 
Body -2.19E-01 1.00E-04 8.76E-01 246 -4.68E+00 2.56E-02 5.36E-02 146 
TSS1500 -4.00E-02 6.09E-06 9.69E-01 245 4.17E+00 3.51E-02 6.32E-02 99 
TSS200 -7.54E-01 1.21E-03 6.13E-01 214 -4.90E+00 3.48E-02 2.62E-02 142 
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Table 3. iAs-associated, differentially methylated CpG sites with significant association to gene expression levels. Associations were calculated 
using Pearson correlation.  
CpG probe 
ID 
Refgene 
Symbol Gene Name 
Expression 
Fold Change 
(HEQ /LEQ) 
p-value 
(U-tAs) 
q-value 
(U-tAs) 
p -value 
(Expression) 
cg16360836 HDAC4 Histone deacetylase 4 9.36E-01 7.02E-05 2.03E-02 2.00E-04
cg24671666 PLEKHG3 
Pleckstrin homology domain 
containing, family G (with RhoGef 
domain) member 3 
7.64E-01 3.30E-04 3.62E-02 1.90E-03
cg10632215 CERK Ceramide kinase 8.61E-01 5.06E-04 4.30E-02 4.00E-03
cg15601244 SH2B2 SH2B adaptor protein 2 8.49E-01 7.31E-05 2.05E-02 4.10E-03
cg26489875 MALAT1 
Metastasis associated lung 
adenocarcinoma transcript 1 (non-
protein coding) 
1.12E+00 4.82E-04 4.20E-02 4.40E-03
cg15883181 RNF213 Ring finger protein 213 8.28E-01 7.63E-05 2.07E-02 4.90E-03
cg18054302 GAK Cyclin G associated kinase 8.86E-01 3.06E-04 3.53E-02 5.30E-03
cg22798758 PTPRE Protein tyrosine phosphatase, receptor type, E 8.61E-01 2.95E-04 3.48E-02 6.00E-03
cg09112262 WDR55 WD repeat domain 55 8.28E-01 4.63E-04 4.13E-02 6.10E-03
cg20851790 RNF213 Ring finger protein 213 8.28E-01 4.25E-04 3.98E-02 6.10E-03
cg07199894 ULK1 Unc-51 like autophagy activating kinase 1 1.15E+00 6.51E-04 4.69E-02 7.80E-03
cg00627621 TRIB1 Tribbles homolog 1 (Drosophila) 8.41E-01 3.35E-04 3.65E-02 1.22E-02
cg15574972 MALAT1 
Metastasis associated lung 
adenocarcinoma transcript 1 (non-
protein coding) 
1.12E+00 1.82E-04 2.89E-02 1.30E-02
cg18312113 SSU72 SSU72 RNA polymerase II CTD phosphatase homolog (S. cerevisiae) 8.76E-01 4.22E-04 3.97E-02 1.72E-02
cg20689294 PTPRE Protein tyrosine phosphatase, receptor type, E 8.61E-01 5.48E-04 4.40E-02 1.77E-02
cg06719391 KCNQ1 Potassium voltage-gated channel, KQT-like subfamily, member 1 8.59E-01 2.91E-05 1.49E-02 1.80E-02
cg02582997 GAK Cyclin G associated kinase 8.86E-01 5.43E-04 4.40E-02 2.07E-02
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cg03041730 GAK Cyclin G associated kinase 8.86E-01 2.99E-05 1.50E-02 2.30E-02
cg24725201 KCNQ1 Potassium voltage-gated channel, KQT-like subfamily, member 1 8.59E-01 1.08E-04 2.36E-02 2.67E-02
cg24089935 KCNQ1 Potassium voltage-gated channel, KQT-like subfamily, member 1 8.59E-01 7.98E-05 2.10E-02 2.77E-02
cg06107260 HDAC4 Histone deacetylase 4 9.36E-01 9.26E-06 1.04E-02 2.94E-02
cg03926050 PPTC7 PTC7 protein phosphatase homolog (S. cerevisiae) 8.13E-01 2.93E-04 3.47E-02 3.86E-02
cg01693193 KCNQ1 Potassium voltage-gated channel, KQT-like subfamily, member 1 8.59E-01 3.04E-05 1.51E-02 3.94E-02
cg04295928 PGAP2 Post-GPI attachment to proteins 2 8.69E-01 3.41E-05 1.57E-02 4.62E-02
cg08438705 SBNO2 Strawberry notch homolog 2 (Drosophila) 8.51E-01 4.91E-04 4.24E-02 4.79E-02
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To note, when contrasted to the total number of DMGs (n=2,705), this represents <1% of the 
total. Representative plots for probes with significant correlation between expression and methylation are 
shown (Figure 5).  
 
	
Figure 5. Representative plots of genes with significant correlation between U-tAs associated DNA 
methylation and U-tAs associated gene expression. 
 
Further analysis of the association between the methylation levels of these 16 genes and birth 
outcomes identified significant associations to gestational age (n=6 probes, n=5 genes), placental weight 
(n=5 probes, n=5 genes), and head circumference (n=1 probe, n=1 gene). Genes with methylation at CpG 
sites associated with U-tAs levels and birth outcomes included: post-GPI attachment to proteins 2 
(PGAP2), protein tyrosine phosphatase, receptor type, E (PTPRE), potassium voltage-gated channel, 
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KQT-like subfamily, member 1 (KCNQ1), cyclin G associated kinase (GAK), WD repeat domain 55 
(WDR55), ring finger protein 213 (RNF213), and  PTC7 protein phosphatase homolog (PPTC7) (Table 
4). 
 
Table 4. CpG sites associated with birth outcomes in the BEAR cohort. Associations between outcomes 
and CpG sites were calculated using Pearson correlation. 
 
Transcription factor enrichment analysis in differentially methylated genes and differentially 
expressed genes 
In order to identify potential upstream regulators that could impact locations of genomic DNA 
methylation, gene expression levels and health outcomes, enrichment analysis for transcription factor 
binding sites was performed. This analysis focused on the 16 genes that showed association between 
differential methylation and gene expression. Binding sites for a total of 36 transcription factors (TFs) 
Birth 
Outcome 
Refgene 
Symbol Gene Name 
CpG probe 
ID p-value R n 
Gestational age PTPRE 
Protein tyrosine 
phosphatase, receptor type, 
E 
cg22798758 3.74E-02 -0.34 38
Gestational age WDR55 WD repeat domain 55 cg09112262 4.08E-02 -0.33 38
Gestational age PTPRE 
Protein tyrosine 
phosphatase, receptor type, 
E 
cg20689294 1.76E-02 -0.38 38
Gestational age KCNQ1 
Potassium voltage-gated 
channel, KQT-like 
subfamily, member 1 
cg06719391 2.63E-02 -0.36 38
Gestational age GAK Cyclin G associated kinase cg02582997 4.35E-02 -0.33 38
Gestational age PGAP2 Post-GPI attachment to proteins 2 cg04295928 2.75E-03 -0.47 38
Placenta weight RNF213 Ring finger protein 213 cg15883181 4.72E-02 0.33 36
Placenta weight PTPRE 
Protein tyrosine 
phosphatase, receptor type, 
E 
cg20689294 3.45E-03 0.47 36
Placenta weight KCNQ1 
Potassium voltage-gated 
channel, KQT-like 
subfamily, member 1 
cg06719391 1.61E-02 0.4 36
Placenta weight GAK Cyclin G associated kinase cg02582997 3.53E-02 0.35 36
Placenta weight PGAP2 Post-GPI attachment to proteins 2 cg04295928 1.20E-02 0.41 36
Head 
circumference PPTC7 
PTC7 protein phosphatase 
homolog (S. cerevisiae) cg03926050 4.73E-02 0.33 36
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were enriched within the gene set when compared to genes with altered expression but no correlation with 
methylation (Table S4). The top five most significant TFs enriched in the gene set included CCCTC-
binding factor (zinc finger protein)-like (CTCF) (p<0.00001), early growth response (EGR) (p<0.00001), 
zinc finger and BTB domain containing 14 (ZF5), GLUT4 enhancer factor (HDBP) (p<0.00001), hairy 
and enhancer of split 1 (HES1) (p=0.00006) (Table S4). 
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CHAPTER 4: DISCUSSION, LIMITATIONS, FUTURE DIRECTIONS AND CONCLUSIONS 
 
In the present study we aimed to better understand the potential functional implications of DNA 
methylation changes associated with prenatal arsenic exposure by coupling the data with mRNA as a 
functional read-out along with subsequent birth outcomes. Using samples obtained from the BEAR cohort 
in Mexico, site-specific DNA methylation patterns were analyzed in cord blood leukocytes of newborns 
as they relate to concentrations of maternal urinary arsenic (U-tAs). Many genes (>2,000) displayed 
altered DNA methylation patterning associated with U-tAs, some of which have been observed in 
previous arsenic-exposed cohorts. However, these changes in DNA methylation were largely unrelated to 
gene expression level, a finding that is highly relevant to ongoing research that does not include 
functional readouts at a transcriptional or proteomic level.  In contrast to earlier work estimating that 
~20% of the genomic response to prenatal iAs is controlled by miRNAs (Rager et al. 2014), the results 
here suggest that the transcriptional response may be minimally (~5% or 16/267) controlled by DNA 
methylation changes. Importantly a set of seven of the differentially methylated genes that were 
predictive of functional change at the mRNA level were also associated with birth outcomes including 
gestational age. These genes were enriched for binding sites for transcription factors and support a 
hypothesis of DNA methylation patterns as “environmental footprints” (Sanders et al. 2014) of 
transcription factor occupancy.   
 When analyzed in an arsenic-independent manner, the relationship between DNA methylation 
and functional gene expression was observed. As may have been anticipated, genes with high levels of 
DNA methylation had on average lower expression levels, and genes with low expression displayed 
higher levels of methylation, a finding that is consistent with previous observations comparing the 
methylation levels of genes according to their expression category (higher versus lower expression) (Bell 
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et al. 2011). Also consistent with prior observations, housekeeping genes were enriched amongst the 
genes with low CpG methylation levels thus potentially contributing to high housekeeping gene 
expression levels, as has been observed previously (Fernandez et al. 2012). Surprisingly, when analyzed 
in an arsenic-dependent manner in the context of U-tAs-associated changes in DNA methylation, there 
was minimal association and no statistical significance between DNA methylation and gene expression on 
a genome-wide level (n=18,761 genes), a result that did not depend on the data normalization method 
used. These results highlight that changes in mRNA expression associated with U-tAs are only weakly 
correlated to changes in gene methylation on a genome-wide scale. Given the focus of much literature 
pertaining to CpG methylation on the gene-silencing effects of DNA methylation (Jones 2012) these 
results may seem unexpected. It is important to note, however, that such low correlations between gene 
expression and DNA methylation levels have been observed previously. For example, the Meissner lab 
studied genome-wide DNA methylation and expression changes across cell types and observed minimal 
correlation (Bock et al. 2012). Similarly, a weak correlation was observed between gene expression and 
gene methylation in neocortex cells (Dosunmu et al. 2012). Highly relevant to the present study, a study 
of lung cells from arsenic-exposed mice showed that overall correlation with gene expression among the 
differentially methylated genes was not statistically significant (Boellmann et al. 2010). Taken together, 
coupling our data from the present study with data from the aforementioned studies highlights the very 
important finding that not all sites with altered DNA methylation are associated with changes in gene 
expression. Therefore, it is an important consideration that some changes in DNA methylation may 
represent permissive marks in the regulation of gene expression as has been proposed (Boellmann et al. 
2010), as opposed to eliciting active changes in functional gene expression.  
We identified CpG methylated sites that best predict gene expression levels by performing 
region-specific analysis.  Probes within CpG islands located in the first exon, 5’ UTR and TSS200 were 
identified as the most predictive of gene expression, however, each representing differential effects on 
transcription. Our research supports previous findings of promoter methylation associated with 
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transcriptional repression and conversely, first exon DNA methylation as a hallmark of transcribed genes 
(Jjingo et al. 2012; Jones 2012). Together our data reveal the functional differences between CpG 
methylation in distinct genomic regions and demonstrate that DNA methylation changes positioned 
within CpG islands of the first exon and TSS200 most accurately predict functional consequences at the 
gene expression level. These findings of genome-position effects are highly relevant in the context of 
other studies of iAs-associated DNA methylation changes as they highlight a mechanism by which to 
predict potentially functional CpG methylation.  
A total of 16 genes, representing <1% of the total DMGs, were identified to have significant 
statistical correlation between changes in U-tAs-associated gene expression and DNA methylation across 
study subjects. Furthermore, seven of these 16 genes also displayed an association between DNA 
methylation and birth outcomes, specifically gestational age, placental weight and head circumference. 
Interestingly, two of the five genes associated with gestational age, namely KCNQ1 and GAK, have also 
been identified in a separate study investigating differentially methylated regions (DMRs) associated with 
gestational age (Lee et al. 2012). Furthermore, these sixteen functionally consequential genes display an 
enrichment for binding sites of specific transcription factors including EGR and CTCF, both  known to be 
altered by arsenic and their modulation may impact various cellular signaling pathways (Simeonova et al. 
2000; Xu et al. 2013). The current research provides insight into the transcriptional regulation that can 
potentially influence DNA methylation patterning and elicit functional change. These results build upon 
recent work where we demonstrated that prenatal exposure to cadmium is associated with changes in CpG 
methylation in cord blood leukocytes with an enrichment of binding sites for transcription factors 
amongst these genes. This finding suggested the potential for “environmental footprints” of prior 
transcription factor occupancy during times of DNA methylation (Sanders et al. 2014). The present study 
provides in silico support for the hypothesis that occupancy of U-tAs-associated transcription factors may 
impact the methylation status of a subset of differentially expressed and functionally consequential genes.  
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This study is not without limitations. The sample size in our study is relatively small thus these 
findings should be further validated in larger cohorts. Nevertheless, the fact that many of the gene targets 
displaying altered methylation and particularly those with association to birth outcomes have been found 
in other studies, provides support for biological relevance. Future work should also investigate whether 
the changes in DNA methylation and/or gene expression observed here are stable throughout time. 
Together these results increase the current understanding of the complex relationships between iAs 
exposure during pregnancy, and epigenetic control of cellular signaling events in the infant cord blood 
that may impact human health.  
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APENDIX  1: TABLE S1 
 
Table S1. U-tAs associated differentially methylated probes (q<0.05) First page shown.  
CpG ID 
RefGene 
Symbol2 Gene Name 
Partial Correlation 
 (U-tAs) 
p-value 
(U-tAs) 
q-value 
(U-tAs) 
cg19815813 A2LD1 gamma-glutamylamine cyclotransferase 5.71E-01 2.72E-04 3.39E-02
cg20367788 AAGAB alpha- and gamma-adaptin binding protein 5.73E-01 2.09E-04 3.06E-02
cg06048605 ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2 6.33E-01 1.81E-05 1.27E-02
cg09632163 ABCA3 ATP-binding cassette, sub-family A (ABC1), member 3 7.14E-01 8.06E-07 5.48E-03
cg25793628 ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 5.48E-01 3.48E-04 3.68E-02
cg27656398 ABCB9 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 9 -5.32E-01 3.33E-04 3.64E-02
cg18016288 ABCC4 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4 -5.77E-01 1.51E-04 2.70E-02
cg08499057 ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 5.81E-01 1.20E-04 2.47E-02
cg11113753 ABCG5 
ATP-binding cassette, sub-family G (WHITE), member 
5 -5.86E-01 8.04E-05 2.11E-02
cg23527366 ABHD14A abhydrolase domain containing 14A 5.36E-01 6.71E-04 4.74E-02
cg15077643 ABI2 abl-interactor 2 6.68E-01 7.74E-06 9.58E-03
cg25004737 ABI2 abl-interactor 2 6.44E-01 2.03E-05 1.31E-02
cg27169846 ABLIM2 actin binding LIM protein family, member 2 6.85E-01 1.85E-06 6.11E-03
cg19635501 ABLIM2 actin binding LIM protein family, member 2 5.84E-01 1.56E-04 2.73E-02
cg04514683 ABP1 drebrin-like 4.42E-01 2.53E-04 3.29E-02
cg17411020 ABR active BCR-related -5.76E-01 2.14E-04 3.09E-02
cg02110776 ABR active BCR-related -5.54E-01 3.80E-04 3.81E-02
cg07646714 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 -6.38E-01 2.39E-05 1.38E-02
cg01369908 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 -6.09E-01 5.39E-05 1.85E-02
cg01178601 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 -5.95E-01 7.58E-05 2.07E-02
cg07834934 ACACA acetyl-CoA carboxylase alpha 6.22E-01 4.94E-05 1.78E-02
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APENDIX 2: TABLE S2 
Table S2.  Differentially methylated probes identified in previously published arsenic research and their relationship to current findings in the 
BEAR cohort. First page shown. 
Author 
CpG probe 
ID 
RefGene 
Symbol Gene Name 
Direction of 
change in high 
arsenic group 
(Previous 
research) 
BEAR 
Partial 
Correlation 
(U-tAs)  
BEAR 
 q-value  
(U-tAs) 
BEAR  
p-value 
(U-tAs) 
Differentially 
Methylated in 
BEAR 
(Yes/No) 
Chanda et 
al. (2006) cg01620719 TP53 
tumor 
protein p53 
Hypermethylated 
promoter 4.28E-01 1.15E-01 6.62E-03 No 
Chanda et 
al. (2006) cg02045224 TP53 
tumor 
protein p53 
Hypermethylated 
promoter 1.12E-01 5.97E-01 4.96E-01 No 
Chanda et 
al. (2006) cg02087342 TP53 
tumor 
protein p53 
Hypermethylated 
promoter -3.33E-01 2.41E-01 4.40E-02 No 
Chanda et 
al. (2006) cg02166782 TP53 
tumor 
protein p53 
Hypermethylated 
promoter -5.15E-02 6.87E-01 7.64E-01 No 
Chanda et 
al. (2006) cg02842899 TP53 
tumor 
protein p53 
Hypermethylated 
promoter 1.28E-01 5.75E-01 4.45E-01 No 
Chanda et 
al. (2006) cg03079681 p16 
cyclin-
dependent 
kinase 
inhibitor 2A 
Hypermethylated 
promoter -7.40E-02 6.58E-01 6.66E-01 No 
Chanda et 
al. (2006) cg06317056 TP53 
tumor 
protein p53 
Hypermethylated 
promoter -8.21E-02 6.47E-01 6.30E-01 No 
Chanda et 
al. (2006) cg06365412 TP53 
tumor 
protein p53 
Hypermethylated 
promoter 3.14E-01 2.50E-01 4.84E-02 No 
Chanda et 
al. (2006) cg07562918 p16 
cyclin-
dependent 
kinase 
inhibitor 2A 
Hypermethylated 
promoter -2.34E-01 3.77E-01 1.40E-01 No 
Chanda et 
al. (2006) cg07760161 TP53 
tumor 
protein p53 
Hypermethylated 
promoter 2.04E-01 4.50E-01 2.23E-01 No 
Chanda et 
al. (2006) cg07991600 TP53 
tumor 
protein p53 
Hypermethylated 
promoter -2.12E-01 4.38E-01 2.07E-01 No 
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 APENDIX 3: TABLE S3 
Table S3. Differentialy expressed genes and their matched changes in gene methylation. Partial correlation denotes the coefficient of the 
association between the methylation at the given CpG site to U-tAs using a multivariate model. Adjusted p-values for false discovery rate are 
represented as q-values. First page shown.  
Column ID 
Refgene 
Symbol Gene Name 
Expression 
FC 
 (HEQ /LEQ) 
Methylation 
Partial 
Correlation 
(U-tAs)  
Methylation 
q-value 
(U-tAs) 
Methylation p-value
(U-tAs) 
cg22534545 ABCD1 
ATP-binding cassette, sub-family D 
(ALD), member 1 8.83E-01 2.10E-01 3.34E-01 1.02E-01
cg27024381 ABCD1 
ATP-binding cassette, sub-family D 
(ALD), member 1 8.83E-01 -3.59E-02 7.05E-01 8.34E-01
cg00091063 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 8.39E-02 6.40E-01 6.11E-01
cg00343022 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 -1.09E-01 6.01E-01 5.06E-01
cg00884680 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 -3.33E-02 7.08E-01 8.45E-01
cg01353464 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 -3.43E-01 1.93E-01 2.50E-02
cg02314846 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 2.62E-01 3.50E-01 1.15E-01
cg06069310 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 6.80E-02 6.62E-01 6.77E-01
cg06239037 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 1.96E-01 4.71E-01 2.52E-01
cg06808967 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 -2.18E-01 4.33E-01 2.01E-01
cg07895684 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 3.01E-01 2.82E-01 6.61E-02
cg10548708 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 -3.25E-01 2.58E-01 5.23E-02
cg15348640 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 2.09E-01 3.93E-01 1.56E-01
cg15427004 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 3.85E-01 1.58E-01 1.51E-02
cg17034030 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 -1.33E-01 5.73E-01 4.39E-01
cg17696234 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 2.01E-01 4.58E-01 2.34E-01
cg24368167 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 4.74E-02 6.92E-01 7.83E-01
cg25525163 ACAA1 acetyl-CoA acyltransferase 1 8.45E-01 3.76E-01 1.88E-01 2.34E-02
cg00337466 ADAM8 ADAM metallopeptidase domain 8 8.37E-01 1.43E-01 4.72E-01 2.54E-01
cg00805360 ADAM8 ADAM metallopeptidase domain 8 8.37E-01 4.07E-01 1.40E-01 1.11E-02
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APENDIX 4: TABLE S4 
Table S4. Enriched transcription factor binding sites in DEGs with correlated changes in gene expression and gene methylation (n=16) 
versus DEGs with no correlation between changes in genes expression and DNA methylation (n=318). 
Transcription 
Factor Binding 
Site Description p-score (DEG)
CTCF CCCTC-binding factor (zinc finger protein) 1.54E-09
EGR1 early growth response 1 1.70E-07
ZF5 zinc finger and BTB domain containing 14 1.37E-06
HDBP1 SLC2A4 regulator 1.19E-05
HES1 hairy and enhancer of split 1, (Drosophila) 6.61E-05
AP2 fatty acid binding protein 4, adipocyte 1.45E-04
MYCMAX c-Myc/Max heterodimer 3.85E-04
XCPE1 X gene core promoter element 1 6.99E-04
GAGA GAGA-Box 9.67E-04
FTF nuclear receptor subfamily 5, group A, member 2 1.24E-03
SP1 Sp1 transcription factor 1.52E-03
DICE Downstream Immunoglobulin Control Element 2.53E-03
E2F2 E2F transcription factor 2 2.98E-03
ATF plasminogen activator, urokinase 3.39E-03
HMTE Human motif ten element 3.85E-03
NRF1 nuclear respiratory factor 1 4.37E-03
CREB cAMP responsive element binding protein 1 4.95E-03
NKX11 NK1 homeobox 1, SAX2 5.44E-03
USF Upstream stimulating factor 5.78E-03
CDE 
Cell cycle-dependent element, CDF-1 binding site (CDE/CHR tandem 
elements regulate cell cycle dependent repression) 6.14E-03
NRSE Neural-restrictive-silencer-element 6.93E-03
CMYC Myelocytomatosis oncogene (c-myc proto-oncogene) 7.59E-03
NMYC 
v-myc avian myelocytomatosis viral oncogene neuroblastoma derived 
homolog 1.02E-02
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E2F4 E2F transcription factor 4, p107/p130-binding 1.31E-02
WHN forkhead box N1 1.31E-02
MAX MYC associated factor X 1.60E-02
GCM1 glial cells missing homolog 1 (Drosophila) 1.93E-02
MYOGENIN Myogenic bHLH protein myogenin (myf4) 1.98E-02
PAX5 paired box 5 3.00E-02
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 3.08E-02
NANOG Nanog homeobox 3.24E-02
MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 3.57E-02
CREB1 cAMP responsive element binding protein 1 3.85E-02
STAT3 
signal transducer and activator of transcription 3 (acute-phase response 
factor) 3.94E-02
HELT helt bHLH transcription factor 4.14E-02
E2F3 E2F transcription factor 3 4.34E-02
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